Rick Austin
Company: Harpoon Therapeutics
Job title: Vice-President Research
Seminars:
Tritac-XR: An Extended-Release T Cell Engager Platform Designed to Minimize Cytokine Release Syndrome 11:15 am
Explore how T cell engagers are potent drugs, but their development can be hindered by cytokine release syndrome (CRS) Understand how TriTAC-XR molecules are engineered T cell engager prodrugs that become slowly activated by proteases in circulation Assess how TriTAC-XR’s extended-release mechanism reduces cytokine levels in cynomolgus monkey while generating pharmacodynamic effects comparable to a…Read more
day: Day Two